Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + tislelizumab + regorafenib for advanced intrahepatic cholangiocarcinoma
ChiCTR2200056067Phase 2Not yet recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Jan 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, regorafenib and gemcitabine in intrahepatic cholangiocarcinoma (ICC), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoint: Objective response rate. Planned start Jan 2022; status: not yet recruiting.
02
Drugs
tislelizumabregorafenibgemcitabine
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2200056067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056067.